kuenhsieh
¦P¾Ç
UID 558
ºëµØ
0
¿n¤À 0
©«¤l 755
¾\ŪÅv 99
µù¥U 2011-7-18 ¥Î¤áµù¥U¤Ñ¼Æ 4664
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1211
36.238.25.127
|
|
³q±`¦b°µµû»ù®É·|±N¥i¯à±¡ªp³]¶i¥h °²³]³ÌÃa±¡ªp¤U Àò§Q°I°h¦h¤Ö ¦A¦ô¥X¤@Ó»ù®æ°Ï¶¡
³Ì²³æªº´N¬O§â¹w¦ô±`§Q°§C¨D¥X¶Q²Q»ù
¦pªGÁÙ¬OÁÙ¬O°÷«K©y´N¦³¨¬°÷ªºªÅ¶¡Åý¥¦ªi°Ê ¤ß²z·|µy·L½ñ¹ê¤@ÂI
¤£¹L°ò©ó¤À´²ì«h ÁÙ¬O¤£n©ñ¤Ó¦h¤ß«ä¦b¤@®a¤½¥qªºªÑ»ù¤W
¦pªG¶Rº¡¤F´NÃöª`¨ä¥L®a¤½¥q§a Teva Pharmaceutical Industries Ltd. ADR (Sectors) | | | | Dec 15, 2017 7:59 p.m. | «Øij | ¦X®æ | teva | ÁÙì$ | ROE% | 4¬Õ¦A% | ±`§Q$m | °t®§% | ±`EPS$ | ªÑ®§$ | ©îªÑ | 2012/12 | 25.8 | - | ¬ü | 15,184 | - | 17.4 | 3.78 | 1:1 | ªÑ»ù$ | 18.6 | 2013/12 | 24.8 | 15 | | 12,828 | 76 | 15.1 | 4.63 | 1:1 | ¹w´Á³ø¹S | 25% | 2014/12 | 23.5 | 16 | | 12,347 | 130 | 14.5 | 4.85 | 1:1 | ²Q$ | 31.2 | 2015/12 | 22.2 | 17 | | 15,345 | 57 | 17.9 | 5.25 | 1:1 | ³ø¹S% | 15% | 2016/12 | 20.8 | 12 | 8 | 13,839 | 82 | 13.4 | 5.24 | 1:1 | ¶Q$ | 83.2 | 2017t | 19.5 | 10 | 3 | 12,395 | 1,175 | 11.2 | 2.98 | 1:1 | ³ø¹S% | 0% | | 18.6 | 11 | 15¡K¥§¡ROE | =(®§+®wÂêÑ)/¥h¦~²b§Q | | ²{¦bPER | 6 | | | | | | | | | | ³Ì²×PER | 12 | ¶R¤£·|Åܪº¤½¥q¡G²£«~¤£·|ÅÜ¡BÀsÀYªÑ¡B·Q3¬íÄÁ´N¤F¸Ñ | | | | ¹w´Á°t®§ | 73% | Teva Pharmaceutical Industries Ltd. ADR (Sectors) | | | | Dec 15, 2017 7:59 p.m. | «Øij | ¦X®æ | teva | ÁÙì$ | ROE% | 4¬Õ¦A% | ±`§Q$m | °t®§% | ±`EPS$ | ªÑ®§$ | ©îªÑ | 2012/12 | 25.8 | - | ¬ü | 15,184 | - | 17.4 | 3.78 | 1:1 | ªÑ»ù$ | 18.6 | 2013/12 | 24.8 | 15 | | 12,828 | 76 | 15.1 | 4.63 | 1:1 | ¹w´Á³ø¹S | 21% | 2014/12 | 23.5 | 16 | | 12,347 | 130 | 14.5 | 4.85 | 1:1 | ²Q$ | 25.9 | 2015/12 | 22.2 | 17 | | 15,345 | 57 | 17.9 | 5.25 | 1:1 | ³ø¹S% | 15% | 2016/12 | 20.8 | 12 | 8 | 13,839 | 82 | 13.4 | 5.24 | 1:1 | ¶Q$ | 68.8 | 2017t | 19.5 | 8 | 3 | 10,000 | 1,175 | 8.9 | 2.98 | 1:1 | ³ø¹S% | 0% | | 18.6 | 10 | 15¡K¥§¡ROE | =(®§+®wÂêÑ)/¥h¦~²b§Q | | ²{¦bPER | 7 | | | | | | | | | | ³Ì²×PER | 12 | Y»{©w¬O¦n¤½¥q¡A¹w´ÁROE«o¤Ó§C¡A½Ð§â¥§¡ROE¥N¶i¨Ó | | | | ¹w´Á°t®§ | 73% |
|
|
|